SINGAPORE (June 18): Hyphens Pharma has launched in Vietnam the Magnezix brand of implants by Syntellix AG.
Magnezix products are designed to provide surgeons and patients with advanced implants to keep broken bone pieces together for healing and growth.
The Magnezix magnesium alloy is an approved bioabsorbable metallic material for orthopaedic implants.
The implants can be dissolved and reabsorbed within the body due to its unique magnesium alloy compound which promotes quicker healing as compared to common implants.
Patients also need not undergo another surgery to remove the implants.
Syntellix is a Germany‐based company that specialises in the research and development, and sales of cutting‐edge bioabsorbable metal implants.
Hyphens Pharma also has an exclusive distribution agreement with Syntellix for the marketing and distribution of its products in Vietnam.
Tan Chwee Choon, executive director of Hyphens Pharma, says, “This is the first time Magnezix is hitting the Vietnam market. Given its accolades and the stamp of approval from Singapore’s Health Science Authority, we believe that Magnezix will be well received by the Vietnamese medical industry; Magnezix will be made available in hospitals and orthopaedic specialist clinics.”
Prof Utz Claassen, founder and CEO of Syntellix, says, “We are convinced that our highly‐developed magnesium technology has the potential to replace conventional titanium, steel and polymer implants in the long term. The coverage of the important Vietnamese market through our partnership with Hyphens Pharma will therefore be a significant milestone and success factor towards the pursuit of our mission of “less pain, less sorrow and less risks” for the good of many patients in the ASEAN region and all over the world.”
Shares in Hyphens Pharma last traded at 20 cents on Monday.
